Gemcitabine elaidate and ONC201 combination therapy inhibits pancreatic cancer in a KRAS mutated syngeneic mouse model

Approximately 90% of pancreatic cancer (PC) contain KRAS mutations. Mutated KRAS activates the downstream oncogenic PI3K/AKT and MEK signaling pathways and induces drug resistance. However, targeting both pathways with different drugs can also lead to access of toxicity. ONC201 targets DR5 to induce...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahato, Ram, Kumar, Virender, Sethi, Bhartu, Staller, Dalton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371096/
https://www.ncbi.nlm.nih.gov/pubmed/37503215
http://dx.doi.org/10.21203/rs.3.rs-3108907/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371096/
https://www.ncbi.nlm.nih.gov/pubmed/37503215
http://dx.doi.org/10.21203/rs.3.rs-3108907/v1

Ejemplares similares